As mRNA delivery technologies continue to expand beyond traditional lipid reagents into polymer-based systems, electroporation platforms, and lipid nanoparticle (LNP) formulations, researchers are increasingly working across multiple transfection modalities within the same experimental pipeline. In these workflows, the compatibility of the mRNA payload itself can become a limiting factor for consistent intracellular expression.
Allele Biotechnology and Pharmaceuticals develops its mRNA reagents with cross-platform delivery in mind. Our constructs — including fluorescent reporters such as mNeonGreen and mScarlet3 — support efficient protein expression across commonly used transfection systems, including LNP-based delivery approaches.
We routinely observe robust expression following LNP-mediated delivery of Allele mRNA, enabling its use in applications ranging from delivery system screening to nanoparticle validation and
